Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Food and Drug Administration has approved a new treatment for people living with HIV.
In clinical trials, the single-tablet regimen of Tivicay (dolutegravir) and Epivir (lamivudine) was as effective as a three-drug treatment.
Full 48-week results comparing dolutegravir plus lamivudine with a three-drug combo were presented at the International AIDS Conference.
A large ongoing study in Botswana has found that about 1 in 150 babies exposed to Tivicay at conception developed such birth defects.
The combo of dolutegravir and lamivudine controlled HIV as well as a triple-drug combo of dolutegravir plus Truvada.
Juluca is a single-tablet regimen for HIV.
Clinicians have presented a pair of case reports of patients going on the HIV medication and experiencing severe mental health reactions.
Two large trials switched participants from three- or four-drug combos to a regimen of Tivicay (dolutegravir) and Edurant (rilpivirine).
The HIV drug is associated with a high rate of insomnia, dizziness and headache, especially among women and those over 60.
The trial will test a regimen of Tivicay (dolutegravir) plus Epivir (lamivudine) against Tivicay and Truvada (tenofovir/emtricitabine).
The regimen of Tivicay (dolutegravir) and Epivir (lamivudine) would be a highly cost-effective first-line option and save a great deal.
Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.
ViiV Healthcare is seeking approval of Tivicay (dolutegravir) to be used as a generic through the U.S. PEPFAR.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.